异基因造血干细胞移植：复发或难治性淋巴瘤的挽救性治疗
Allogeneic Hematopoietic Stem Cell Transplantation: A Salvage Treatment for Relapsed or Refractory Lymphoma.
作者信息
Wang Jing-Shi, Wang Zhao, Wang Yi-Ni, Wu Lin, Fu Li, Wei Na
机构信息
Department of Hematology, Beijing Friendship Hospital, Capital Medical University, No. 95 Yong'an Road, Xicheng District, Beijing, 100050 People's Republic of China.
出版信息
Indian J Hematol Blood Transfus. 2015 Dec;31(4):426-33. doi: 10.1007/s12288-014-0497-7. Epub 2015 Jan 9.
To analyze the efficacy and safety of allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in patients with relapsed or refractory lymphoma, the therapeutic efficacy, safety, and survival of 23 patients were evaluated. There were 18 (78.3 %) patients with relapsed lymphoma and 5 (21.7 %) patients with refractory lymphoma. Patients were grafted from human leukocyte antigen (HLA)-matched (10) or mismatched (7) related donors, or matched unrelated donors (6). The responses after Allo-HSCT included 13 (56.5 %) cases of complete remission, 5 (21.7 %) cases of partial remission, and 5 (21.7 %) cases of progressive disease. Overall, 16 of 23 patients were alive at a median follow up of 1,035 days (range 60-2,613), five patients died because of non-relapsed mortality, and two patients died of progressive disease. Progression-free survival rates were 64.6 and 48.4 % at 12 and 24 months, respectively, and overall survival rates were 68.6 and 59.5 % at 12 and 24 months, respectively. Allo-HSCT may be a salvage treatment for relapsed or refractory lymphoma. Myeloablative conditioning regimens may be effective and safe.
为分析异基因造血干细胞移植（Allo-HSCT）治疗复发或难治性淋巴瘤患者的疗效及安全性，对23例患者的治疗效果、安全性及生存情况进行了评估。其中18例（78.3%）为复发淋巴瘤患者，5例（21.7%）为难治性淋巴瘤患者。患者的供体来源为人类白细胞抗原（HLA）配型相合的相关供体（10例）、配型不相合的相关供体（7例）或配型相合的无关供体（6例）。Allo-HSCT后的反应包括完全缓解13例（56.5%）、部分缓解5例（21.7%）及疾病进展5例（21.7%）。总体而言，23例患者中有16例在中位随访1035天（范围60 - 2613天）时仍存活，5例患者因非复发死亡率死亡，2例患者死于疾病进展。无进展生存率在12个月和24个月时分别为64.6%和48.4%，总生存率在12个月和24个月时分别为68.6%和59.5%。Allo-HSCT可能是复发或难治性淋巴瘤的一种挽救性治疗方法。清髓性预处理方案可能有效且安全。
Zotero 插件